Mesoblast Limited

MSB

AU000000MSB8

Biotechnology & Medical Research

Market Closed - Australian S.E. Other stock markets 02:10:52 2024-06-03 EDT			5-day change	1st Jan Change
1.105 ^AUD	-0.45%		-4.33%	+256.45%

05-01	Mesoblast Limited Announces Board and Committee Changes	CI
04-01	ADRs End Higher; Connect Biopharma Climbs 26%	DJ

Mesoblast Limited Announces the Cessation of Brian Jamieson as Director Effective from 31 March 2019

April 05, 2019 at 01:56 am

Mesoblast Limited announced the cessation of Brian Jamieson as director effective from 31 March 2019.

Latest news about Mesoblast Limited

Mesoblast Limited Announces Board and Committee Changes	05-01	CI
ADRs End Higher; Connect Biopharma Climbs 26%	04-01	DJ
ADRs End Lower; NuCana Slides 15%	03-28	DJ
ADRs End Lower; Quhuo Drops 53%	03-26	DJ
FDA Says Mesoblast Trial Data Sufficient to Support BLA Submission	03-26	MT
Sector Update: Health Care Stocks Advance Late Afternoon	03-26	MT
Top Midday Gainers	03-26	MT
Sector Update: Health Care Stocks Steady Premarket Tuesday	03-26	MT
Wall Street Set to Open Modestly Higher Tuesday Ahead Consumer Confidence Reading	03-26	MT
Top Premarket Gainers	03-26	MT
Mesoblast Shares Jump After FDA Nod for Submission of Remestemcel-L Application	03-26	DJ
Mesoblast to Resubmit Application for Potential Pediatric Treatment of Graft Versus Host Disease; Shares Gain Pre-Bell	03-26	MT
United States Food & Drug Administration Notifies Mesoblast Limited of Available Clinical Data from Phase 3 Trial Appear Sufficient to Support BLA Submission for Remestemcel-L in Children with Steroid-Refractory Acute Graft Versus Host Disease	03-25	CI
Mesoblast Limited(ASX:MSB) added to S&P/ASX Emerging Companies Index	03-17	CI
Mesoblast Raises AU$97 Million From Entitlement Offer, Institutional Placement	03-14	MT
Mesoblast Raises AU$97 Million for Phase Three Registration Trials	03-14	MT
Sector Update: Health Care Stocks Softer Late Afternoon	03-11	MT
Sector Update: Health Care Stocks Decline in Afternoon Trading	03-11	MT
Sector Update: Health Care	03-11	MT
Top Stories at Midday: Bally's Gets Takeover Proposal; Eli Lilly's Eczema Study Results; Reddit's Expected IPO Price Range; FDA Backs Mesoblast Heart Therapy's Approval Pathway	03-11	MT
Sector Update: Health Care Stocks Lean Lower Premarket Monday	03-11	MT
Mesoblast Says FDA Supports Accelerated Approval Pathway for Heart Failure Treatment	03-11	MT
Mesoblast Secures Backing from US FDA for Potential Fast-Track Approval of Heart Failure Treatment	03-11	MT
Mesoblast Limited Announces United States Food & Drug Administration Supports Accelerated Approval Pathway for Rexlemestrocel-L in End-Stage Heart Failure Patients with A Left Ventricular Assist Device	03-10	CI
Mesoblast Narrows H1 FY24 Loss; Shares Down 3%	02-28	MT

Mesoblast Limited is an Australia-based is developing a range of late-stage product candidates derived from its proprietary mesenchymal lineage cell therapy technology platforms. The Companyâs Remestemcel-L is mesenchymal lineage stromal cell product platform and is in late-stage development for treatment of systemic inflammatory diseases, including Pediatric steroid refractory acute Graft versus Host Disease (SR-aGVHD), acute respiratory distress syndrome (ARDS) and Biologic refractory inflammatory bowel disease. Its Rexlemestrocel-L is mesenchymal lineage precursor cell product platform and is in late-stage development for treatment of advanced chronic heart failure (CHF) and chronic low back pain (CLBP) due to degenerative disc disease. Two products are commercialized in Japan and Europe by the Companyâs licensees, and it has a commercial partnership in Europe and China for certain Phase III assets.

Sector

Biotechnology & Medical Research

Calendar

2024-08-27 - Q4 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Ratings for Mesoblast Limited

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

1.11 AUD

Average target price

1.1 AUD

Spread / Average Target

-0.90%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
MESOBLAST LIMITED	+256.45%	841M
MODERNA, INC.	+49.12%	54.63B
IQVIA HOLDINGS INC.	-4.82%	39.92B
LONZA GROUP AG	+37.52%	38.82B
ICON PUBLIC LIMITED COMPANY	+15.63%	26.86B
CELLTRION, INC.	-12.56%	26.22B
ALNYLAM PHARMACEUTICALS, INC.	-21.80%	18.78B
UNITED THERAPEUTICS CORPORATION	+25.41%	12.21B
BIO-TECHNE CORPORATION	+2.23%	12.16B
MEDPACE HOLDINGS, INC.	+27.15%	11.94B

Other Biotechnology & Medical Research